Crossmark

Response to Letter. “Romosozumab and cardiovascular safety- should we learn lessons from Pioglitazone?.”

Published Online: 2022-02-18

Published Print: 2022-06

Authors

Tominaga, Ayako

Wada, Keiji

Okazaki, Ken

Nishi, Hideharu

Terayama, Yasushi

Kato, Yoshiharu
License Information

Text and Data Mining valid from 2022-02-18

Version of Record valid from 2022-02-18
More Information

Article History

Received: 1 January 2022

Accepted: 3 January 2022

First Online: 18 February 2022

Document is current